港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

维昇药业-B

46.600

-0.950-2.00%

成交量：5.32万

成交额：250.01万

市值：53.12亿

市盈率：-23.94

高：47.550

开：47.450

低：46.250

收：47.550

数据加载中...

总览公司新闻公告

【维升药业-B(02561.HK)：选举付山继任董事会主席】智通财经APP讯，维升药业-B(02561.HK)发布公告，

维升药业-B(02561)：选举付山继任董事会主席

维升药业-B06月27日主力净流出29.5万元散户资金买入

25家中国内分泌与代谢领域创新药公司获融资！

维升药业-B06月19日主力净流出27.7万元散户资金买入

维升药业-B06月18日主力净流入28.1万元散户资金抛售

维升药业-B06月17日主力净流出73.9万元散户资金买入

港股异动 | 维升药业-B(02561)涨超6% 隆培促生长素本地化生产进一步落实那韦培肽新药申请获FDA受理

医药生物IPO“港漂”热潮：三大热门创新药成焦点，恒瑞医药4个月便实现A+H

维升药业的独立性与生长激素困局

维升药业-B盘中涨超6% 公司预计隆培促生长素于下半年在国内获批上市

维升药业-B05月28日主力净流出42.8万元散户资金买入

三家顶级投行一致推荐，维升药业-B(2561.HK)为何能够获资本共识？

维升药业-B05月26日遭主力抛售69.2万元

维升药业-B05月22日获主力加仓47.4万元

维升药业-B05月21日主力净流入52.8万元散户资金抛售

【热门行业】港股医药股集体走强创新出海驱动估值重构

港股异动 | 维升药业-B(02561)涨超5% 治疗软骨发育不全药物那韦培肽完成中国2期临床试验

维升药业那韦培肽完成中国2期临床试验，用于治疗软骨发育不全

JV孵化，如何养成2025年港股创新药第一股？ | 专访维梧资本管理合伙人付山

医药魔方Invest

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/02561/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02561","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02561\",,,,,undefined,":{"symbol":"02561","market":"HK","secType":"STK","nameCN":"维昇药业-B","latestPrice":46.6,"timestamp":1751011733028,"preClose":47.55,"halted":0,"volume":53200,"delay":0,"floatShares":113999999,"shares":113999999,"eps":-1.946273,"marketStatus":"休市中","change":-0.95,"latestTime":"06-27 16:08:53","open":47.45,"high":47.55,"low":46.25,"amount":2500125,"amplitude":0.02734,"askPrice":46.6,"askSize":100,"bidPrice":46.5,"bidSize":500,"shortable":0,"etf":0,"ttmEps":-1.946273,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1751247000000},"marketStatusCode":7,"adr":0,"listingDate":1742486400000,"exchange":"SEHK","adjPreClose":47.55,"openAndCloseTimeList":[[1750987800000,1750996800000],[1751000400000,1751011200000]],"volumeRatio":1.7745163412699863,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02561\",,,,,undefined,":{"symbol":"02561","floatShares":113999999,"roa":"-29.52%","roe":"-57.66%","lyrEps":-1.946273,"volumeRatio":1.7745163412699863,"shares":113999999,"dividePrice":0,"high":47.55,"amplitude":0.02734,"preClose":47.55,"low":46.25,"week52Low":39.25,"pbRate":"20.11","psRate":"1747.60","week52High":69.15,"institutionHeld":0,"latestPrice":46.6,"committee":0.666667,"eps":-1.946273,"divideRate":0,"volume":53200,"delay":0,"ttmEps":-1.946273,"open":47.45,"prevYearClose":68.8,"prevWeekClose":48.7,"prevMonthClose":45.1,"prevQuarterClose":53.15,"fiveDayClose":48.7,"twentyDayClose":45.1,"sixtyDayClose":57.25},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02561\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2546747823","title":"【维升药业-B(02561.HK)：选举付山继任董事会主席】智通财经APP讯，维升药业-B(02561.HK)发布公告，","url":"https://stock-news.laohu8.com/highlight/detail?id=2546747823","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546747823?lang=zh_cn&edition=fundamental","pubTime":"2025-06-27 23:02","pubTimestamp":1751036525,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2546747356","title":"维升药业-B(02561)：选举付山继任董事会主席","url":"https://stock-news.laohu8.com/highlight/detail?id=2546747356","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546747356?lang=zh_cn&edition=fundamental","pubTime":"2025-06-27 23:02","pubTimestamp":1751036525,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维升药业-B 发布公告，Michael Wolff JENSEN先生及Jan Mller MIKKELSEN先生已于股东周年大会结束时退任。董事会进一步宣布，其已建议及选举付山先生继任董事会主席，自股东周年大会结束起生效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1311318.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2546719685","title":"维升药业-B06月27日主力净流出29.5万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2546719685","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546719685?lang=zh_cn&edition=fundamental","pubTime":"2025-06-27 16:15","pubTimestamp":1751012151,"startTime":"0","endTime":"0","summary":"06月27日, 维升药业-B股价跌2.00%，报收46.60元，成交金额250.0万元，换手率0.05%，振幅2.73%，量比1.77。维升药业-B今日主力资金净流出29.5万元，上一交易日主力净流出0万元。该股近5个交易日下跌4.31%，主力资金累计净流出3.9万元；近20日主力资金累计净流入350.6万元，其中净流入天数为5日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250627173305a7208de5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250627173305a7208de5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2546290689","title":"25家中国内分泌与代谢领域创新药公司获融资！","url":"https://stock-news.laohu8.com/highlight/detail?id=2546290689","media":"创鉴汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546290689?lang=zh_cn&edition=fundamental","pubTime":"2025-06-25 17:06","pubTimestamp":1750842372,"startTime":"0","endTime":"0","summary":"内分泌与代谢疾病因患者基数庞大且临床需求持续增长，成为创新药研发的重要方向。据公开数据统计，2025年至今，该领域至少发生25起创新药公司融资事件，已披露融资总额超125亿元。AI、新分子实体创新技术引领大额融资：11家公司获得亿元及以上融资。维升药业：内分泌疾病药物研发公司3月21日，维升药业在港交所IPO，募资约6.72亿港元。珂阑医药：胆固醇代谢创新药研发公司2月21日消息，珂阑医药完成超亿元人民币A+轮融资。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250625171409a4bd09c6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250625171409a4bd09c6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02561","BK1574","06978","BK1161"],"gpt_icon":0},{"id":"2544157782","title":"维升药业-B06月19日主力净流出27.7万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2544157782","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544157782?lang=zh_cn&edition=fundamental","pubTime":"2025-06-19 16:15","pubTimestamp":1750320951,"startTime":"0","endTime":"0","summary":"06月19日, 维升药业-B股价跌3.45%，报收49.00元，成交金额320.1万元，换手率0.06%，振幅5.71%，量比0.46。维升药业-B今日主力资金净流出27.7万元，上一交易日主力净流入28.1万元。该股近5个交易日上涨1.55%，主力资金累计净流入325.2万元；近20日主力资金累计净流入199.9万元，其中净流入天数为4日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250619174038a4b25192&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250619174038a4b25192&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2544978997","title":"维升药业-B06月18日主力净流入28.1万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2544978997","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544978997?lang=zh_cn&edition=fundamental","pubTime":"2025-06-18 16:15","pubTimestamp":1750234546,"startTime":"0","endTime":"0","summary":"06月18日, 维升药业-B股价涨2.01%，报收50.75元，成交金额291.7万元，换手率0.05%，振幅3.32%，量比0.42。维升药业-B今日主力资金净流入28.1万元，上一交易日主力净流出73.9万元。该股近5个交易日上涨7.98%，主力资金累计净流入352.9万元；近20日主力资金累计净流入275.0万元，其中净流入天数为5日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250618173908a71039ee&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250618173908a71039ee&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2544685549","title":"维升药业-B06月17日主力净流出73.9万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2544685549","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544685549?lang=zh_cn&edition=fundamental","pubTime":"2025-06-17 16:15","pubTimestamp":1750148126,"startTime":"0","endTime":"0","summary":"06月17日, 维升药业-B股价跌7.53%，报收49.75元，成交金额942.4万元，换手率0.16%，振幅7.99%，量比1.60。维升药业-B今日主力资金净流出73.9万元，上一交易日主力净流入100.7万元。该股近5个交易日上涨3.22%，主力资金累计净流入324.8万元；近20日主力资金累计净流入299.8万元，其中净流入天数为5日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250617172843a4adfcbd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250617172843a4adfcbd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2543416623","title":"港股异动 | 维升药业-B(02561)涨超6% 隆培促生长素本地化生产进一步落实 那韦培肽新药申请获FDA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2543416623","media":"智通财经","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543416623?lang=zh_cn&edition=fundamental","pubTime":"2025-06-16 15:14","pubTimestamp":1750058044,"startTime":"0","endTime":"0","summary":"消息面上，6月9日，维升药业与药明生物宣布，维升药业核心产品隆培促生长素商业化批次的技术转移项目正式落地成都，双方还将在该基地合作建设国内首条双腔冻干制剂生产线，这一创新型药物制剂生产技术能极大地提升药物稳定性及临床使用便捷性。据悉，2023年12月，维升药业与药明生物已就隆培促生长素的技术转移首次达成战略合作。维升药业拥有那韦培肽在大中华区的独家开发、生产和商业化权利。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1305615.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02561","BK1161"],"gpt_icon":0},{"id":"2543681110","title":"医药生物IPO“港漂”热潮：三大热门创新药成焦点，恒瑞医药4个月便实现A+H","url":"https://stock-news.laohu8.com/highlight/detail?id=2543681110","media":"时代周报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543681110?lang=zh_cn&edition=fundamental","pubTime":"2025-06-13 19:50","pubTimestamp":1749815428,"startTime":"0","endTime":"0","summary":"部分企业“弃A转港”，或为这波港股医药生物IPO热潮添一把火。排队IPO企业方面，截至今年5月31日，港股医药生物IPO申报企业共有20家。医药生物企业扎堆赴港IPO，或与A股IPO审核趋严有关。未盈利医药生物企业扎堆赴港IPO，与港交所创新性推出的18A上市规则有关。例如，恒瑞医药、派格生物、觅瑞等均在招股书中明确提出“出海”计划。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250613195043951b08b8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250613195043951b08b8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","09606","06978","BK1574","02561","01276","BK1161"],"gpt_icon":1},{"id":"2542511170","title":"维升药业的独立性与生长激素困局","url":"https://stock-news.laohu8.com/highlight/detail?id=2542511170","media":"市值观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542511170?lang=zh_cn&edition=fundamental","pubTime":"2025-06-12 20:02","pubTimestamp":1749729766,"startTime":"0","endTime":"0","summary":"目前，维升药业旗下最重磅产品为隆培促生长素，已完成三期临床，其上市许可申请已于2024年3月获国家药监局受理，预计在2025年将获准上市。这足见维升药业上市的紧迫性。2023年12月，维升药业与药明生物签订协议，后者作为接收点参与大股东技术转移，最终完成隆培促生长素药物原液的本地商业化供应，预计于2028年实现。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250612202416a4a52a9d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250612202416a4a52a9d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","HSTECH","02561","HSCEI"],"gpt_icon":1},{"id":"2540453797","title":"维升药业-B盘中涨超6% 公司预计隆培促生长素于下半年在国内获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2540453797","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540453797?lang=zh_cn&edition=fundamental","pubTime":"2025-06-03 10:58","pubTimestamp":1748919501,"startTime":"0","endTime":"0","summary":"维升药业-b盘中涨超6%，截至发稿，涨5.95%，报47.2港元，成交额131.9万港元。该行续指，根据公司招股书，公司研发进展最快的是隆培促生长素，公司预计在2025H2国内获批上市；国内长效生长激素市场相对蓝海，弗若斯特沙利文预测有望在2030年达到211亿元，公司的产品优势明显，有望获得较大的市场分额。目前，公司拥有2款独特品种，分别为那韦培肽和帕罗培特立帕肽，后者有望在2025年底递交上市申请，一齐为公司的长期增长提供驱动力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250603110447a6f7eb33&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250603110447a6f7eb33&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2538429042","title":"维升药业-B05月28日主力净流出42.8万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2538429042","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538429042?lang=zh_cn&edition=fundamental","pubTime":"2025-05-28 16:15","pubTimestamp":1748420116,"startTime":"0","endTime":"0","summary":"05月28日, 维升药业-B股价跌4.27%，报收44.80元，成交金额271.1万元，换手率0.05%，振幅4.27%，量比1.19。维升药业-B今日主力资金净流出42.8万元，上一交易日主力净流出0万元。该股近5个交易日下跌2.19%，主力资金累计净流出107.3万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出255.9万元，其中净流出天数为6日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250528171932a6f02037&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250528171932a6f02037&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02561","BK1161"],"gpt_icon":0},{"id":"2538138654","title":"三家顶级投行一致推荐，维升药业-B(2561.HK)为何能够获资本共识？","url":"https://stock-news.laohu8.com/highlight/detail?id=2538138654","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538138654?lang=zh_cn&edition=fundamental","pubTime":"2025-05-28 07:58","pubTimestamp":1748390286,"startTime":"0","endTime":"0","summary":"近一个月来，深耕内分泌治疗领域的维升药业持续在资本市场引发关注，先后获得了Morgan Stanley、Jefferies，以及中信证券三家机构“增持”及“买入”评级。价值低估的内分泌赛道黑马从三家机构给出的目标价来看，当前维升药业股价隐含显著低估空间，长期价值释放通道已逐渐清晰。目前，其上市许可申请已获国家药监局受理，预计将在今年下半年获批上市。国内尚无相关针对性药物获批，市场格局良好。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505280758139767b4b9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505280758139767b4b9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02561","BK1161"],"gpt_icon":0},{"id":"2538728521","title":"维升药业-B05月26日遭主力抛售69.2万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2538728521","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538728521?lang=zh_cn&edition=fundamental","pubTime":"2025-05-26 16:15","pubTimestamp":1748247332,"startTime":"0","endTime":"0","summary":"05月26日, 维升药业-B股价跌3.26%，报收45.95元，成交金额166.9万元，换手率0.03%，振幅4.84%，量比0.68。维升药业-B今日主力资金净流出69.2万元，上一交易日主力净流出42.7万元。该股近5个交易日上涨4.43%，主力资金累计净流出11.7万元；近20日主力资金累计净流出334.3万元，其中净流出天数为6日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250526172333a6ed5461&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250526172333a6ed5461&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02561","BK1161"],"gpt_icon":0},{"id":"2537991145","title":"维升药业-B05月22日获主力加仓47.4万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2537991145","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537991145?lang=zh_cn&edition=fundamental","pubTime":"2025-05-22 16:15","pubTimestamp":1747901747,"startTime":"0","endTime":"0","summary":"05月22日, 维升药业-B股价涨2.84%，报收47.05元，成交金额444.6万元，换手率0.08%，振幅8.42%，量比3.03。维升药业-B今日主力资金净流入47.4万元，上一交易日主力净流入52.8万元。该股近5个交易日上涨3.73%，主力资金累计净流入100.2万元；近20日主力资金累计净流入144.0万元，其中净流入天数为6日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250522173801a6e8a900&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250522173801a6e8a900&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02561","BK1161"],"gpt_icon":0},{"id":"2537985035","title":"维升药业-B05月21日主力净流入52.8万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2537985035","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537985035?lang=zh_cn&edition=fundamental","pubTime":"2025-05-21 16:15","pubTimestamp":1747815356,"startTime":"0","endTime":"0","summary":"05月21日, 维升药业-B股价涨3.86%，报收45.75元，成交金额210.5万元，换手率0.04%，振幅4.77%，量比1.50。维升药业-B今日主力资金净流入52.8万元，上一交易日主力净流出0万元。该股近5个交易日下跌1.40%，主力资金累计净流入52.8万元；近20日主力资金累计净流入96.6万元，其中净流入天数为5日。该股主力净额占比0.01%，港股市场排名337/2645。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250521173203a6e737ee&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250521173203a6e737ee&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2537082266","title":"【热门行业】港股医药股集体走强 创新出海驱动估值重构","url":"https://stock-news.laohu8.com/highlight/detail?id=2537082266","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537082266?lang=zh_cn&edition=fundamental","pubTime":"2025-05-21 14:03","pubTimestamp":1747807396,"startTime":"0","endTime":"0","summary":"2024年度业绩暨现金分红说明会上，恒瑞医药称其创新药出海成效显着，目前，公司已实现13项创新药海外授权，交易总额约为140亿美元。“出海”已成为中国医药企业的重要战略。今年4月中美关税摩擦以来，仍有多项药品出海BD交易达成，显示创新药出海势头仍然强劲。","market":"other","thumbnail":"https://static.szfiu.com/news/20250106/NDdkYmY2NGUzZGQ4YzY5MzkwZTM0MzQwMzk2Mjg3Mzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/NDdkYmY2NGUzZGQ4YzY5MzkwZTM0MzQwMzk2Mjg3Mzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1959053","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ08YR35.GBP","BK1161","LU0067412154.USD","LU1807302812.USD","LU0501845795.SGD","BK1574","02273","02561","LU1152091754.HKD","BK1583","LU1226288253.USD","01801","IE00B543WZ88.USD","BK1593","BK1515","06160","01093","01530","BK1219","BK1588","LU1951186391.HKD","LU1969619763.USD","BK1207","LU1152091168.USD","LU1993786604.SGD","BK1521","09969","IE00BZ08YT58.USD","SG9999004220.SGD","LU1008478684.HKD","IE00B031HY20.USD","LU1226287529.USD","IE00B5MMRT66.SGD","LU0588546209.SGD","SG9999004311.SGD","02367","BK1191","BK1589","02105","03692","09606","IE0008369823.USD","LU1226287875.USD","LU2488822045.USD","LU1226287792.SGD","159718","LU0072913022.USD","LU2328871848.SGD","LU0880133367.SGD","BK1500"],"gpt_icon":1},{"id":"2535946327","title":"港股异动 | 维升药业-B(02561)涨超5% 治疗软骨发育不全药物那韦培肽完成中国2期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2535946327","media":"智通财经","labels":["dataReport","movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535946327?lang=zh_cn&edition=fundamental","pubTime":"2025-05-13 14:54","pubTimestamp":1747119240,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，维升药业-B涨超5%，截至发稿，涨5.39%，报46.9港元，成交额217.21万港元。消息面上，5月12日，维升药业宣布其在研的用于治疗软骨发育不全的那韦培肽中国2期临床试验已全部顺利完成，并于近期在国家药监局“药物临床试验登记与信息公示平台”登记临床试验结果信息。据悉，那韦培肽中国2期临床试验针对中国2至10岁ACH患儿，采用每周一次皮下给药的方式，旨在安全治疗剂量下持续提供活性CNP。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1292438.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1161","02561","03347","BK1141","BK1576"],"gpt_icon":0},{"id":"2534291132","title":"维升药业那韦培肽完成中国2期临床试验，用于治疗软骨发育不全","url":"https://stock-news.laohu8.com/highlight/detail?id=2534291132","media":"时代财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534291132?lang=zh_cn&edition=fundamental","pubTime":"2025-05-12 18:55","pubTimestamp":1747047306,"startTime":"0","endTime":"0","summary":"本文来源：时代财经5月12日，维升药业宣布其在研的用于治疗软骨发育不全的那韦培肽中国 2 期临床试验已全部顺利完成，并于近期在国家药监局“药物临床试验登记与信息公示平台”登记临床试验结果信息。据维升药业介绍，那韦培肽中国2期临床试验针对中国2至10岁ACH患儿，采用每周一次皮下给药的方式，旨在安全治疗剂量下持续提供活性CNP。另据沙利文数据，2023年中国软骨发育不全的患病人数为5.12万例，其中可以治疗的儿童约1万例。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025051219180797572666&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025051219180797572666&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1161","02561","03347","BK1141","BK1576"],"gpt_icon":0},{"id":"2534260464","title":"JV孵化，如何养成2025年港股创新药第一股 ？ | 专访维梧资本管理合伙人付山","url":"https://stock-news.laohu8.com/highlight/detail?id=2534260464","media":"医药魔方Invest","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534260464?lang=zh_cn&edition=fundamental","pubTime":"2025-05-12 08:24","pubTimestamp":1747009462,"startTime":"0","endTime":"0","summary":"维梧资本管理合伙人付山说到，“今天看，这条路是适合维升药业发展的，优秀的产品需要杰出的团队花时间去专注耕耘，维升沉淀出了成果。”借由维升药业登陆港股的契机，医药魔方Invest专访了维升药业控股股东及基石投资者——维梧资本管理合伙人付山。维梧资本管理合伙人付山领先行业的JV孵化2018年，维梧资本一手孵化了维升药业：Ascendis Pharma本就是维梧资本在欧美的被投企业。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250512121205a6dbb033&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250512121205a6dbb033&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","HSTECH","BK1161","02561","06978","HSCEI"],"gpt_icon":1}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":65,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02561\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02561\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02561\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":2,"updateTime":1746288000000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02561\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02561","date":"2025-06-27","current":-26.600431,"percent":0.779661,"low":-30.760225,"twenty":-28.46744,"median":-27.491566,"eighty":-26.131215,"high":-17.514985,"avg":-26.601134,"sd":3.088168,"marketCap":5308991862},"quantilePoints":[{"date":"2025-04-03","current":-21.475965,"twenty":-22.637245,"median":-22.569747,"eighty":-22.098421,"marketCap":5724824916},{"date":"2025-04-11","current":-18.134639,"twenty":-22.558476,"median":-18.349759,"eighty":-18.045823,"marketCap":4802017317},{"date":"2025-04-17","current":-25.787715,"twenty":-25.955056,"median":-22.513392,"eighty":-18.141011,"marketCap":4682394110},{"date":"2025-04-25","current":-29.965674,"twenty":-27.695216,"median":-22.653961,"eighty":-18.190408,"marketCap":5445704099},{"date":"2025-05-02","current":-28.244363,"twenty":-27.861811,"median":-26.066617,"eighty":-18.349759,"marketCap":5143797909},{"date":"2025-05-09","current":-27.581562,"twenty":-28.248468,"median":-27.028836,"eighty":-20.850724,"marketCap":5058352761},{"date":"2025-05-16","current":-27.481285,"twenty":-28.307048,"median":-27.470681,"eighty":-22.305907,"marketCap":5081138134},{"date":"2025-05-23","current":-29.180898,"twenty":-28.483617,"median":-27.481285,"eighty":-22.603559,"marketCap":5411526040},{"date":"2025-05-30","current":-27.585218,"twenty":-28.483617,"median":-27.495492,"eighty":-22.648389,"marketCap":5138101566},{"date":"2025-06-06","current":-26.147365,"twenty":-28.307048,"median":-27.481285,"eighty":-24.987287,"marketCap":5212154028},{"date":"2025-06-13","current":-28.707887,"twenty":-28.307048,"median":-27.486097,"eighty":-25.744296,"marketCap":5724824916},{"date":"2025-06-20","current":-27.87701,"twenty":-28.483617,"median":-27.500076,"eighty":-26.010837,"marketCap":5548238276},{"date":"2025-06-27","current":-26.600431,"twenty":-28.46744,"median":-27.491566,"eighty":-26.131215,"marketCap":5308991862}],"updateTime":1751088863185}}}